查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1870799

噬菌体市场按应用、最终用户、噬菌体类型、给药途径、製剂和生产过程划分－2025-2032年全球预测

Bacteriophage Market by Application, End User, Phage Type, Administration Route, Formulation, Production Process - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，噬菌体市场规模将达到 7,661 万美元，复合年增长率为 5.44%。

关键市场统计数据
基准年 2024 5015万美元
预计年份：2025年 5283万美元
预测年份 2032 7661万美元
复合年增长率 (%) 5.44%

噬菌体技术的策略应用及市场现况：研发、监管对话及影响跨产业应用路径的因素

噬菌体科学已从微生物学的一个细分领域发展成为一个跨学科平台，涵盖治疗、诊断、农业、食品安全和动物健康等多个领域。基因组工程、製剂科学和可扩展生产平台的最新进展提高了基于噬菌体的解决方案的技术可行性，同时，快速病原体检测和噬菌体分型技术的进步也增强了其在标靶干预方面的提案。因此，包括研究机构、医院、食品加工商和农场在内的相关人员正在重新评估噬菌体在抗菌药物管理和生物安全策略框架中的定位。

识别噬菌体科学、商业化、临床应用和生产製造的变革性变化，以推动新的策略转折点。

近年来，一系列变革性力量重新定义了噬菌体从实验室概念转变为可行的解决方案。精准基因组编辑技术的进步使得建构具有客製化宿主范围和有效载荷的工程化噬菌体成为可能，从而提高了其疗效和商业性吸引力。同时，快速诊断技术和改进的生物感测器整合透过缩短标靶时间和实现适应性治疗策略，增强了噬菌体产品的临床和农场应用价值。这些技术的融合正在推动噬菌体产品架构从「一刀切」模式转变为更模组化和靶向的模式。

评估2025年美国关税对噬菌体供应链、成本结构、国际贸易流量和国内生产的累积影响

2025年美国关税政策可能对噬菌体产品的研发和分销的经济效益和物流产生重大影响。进口实验室试剂、专用一次性系统和分析设备关税带来的成本压力可能会增加研究机构和契约製造的上游工程支出。因此，筹资策略将转向拥有国内生产能力和多元化采购管道的供应商，企业需要将关税风险纳入采购计画和价格谈判中。

关键细分市场分析突显了应用、最终用户、噬菌体分类、给药途径、製剂和生产方法对商业化的影响。

細項分析阐明了技术需求、采用趋势和商业模式如何因应用、最终用户、噬菌体类型、给药途径、製剂选择和生产流程的不同而有所差异。在应用领域中，噬菌体的应用案例涵盖农业、兽医、诊断、食品安全和人类治疗。在农业领域，重点在于植物保护、种子处理和土壤改良，每种应用对稳定性、给药方法和监管证据的要求各不相同。兽医学领域又细分为水产养殖、伴侣动物和畜牧业，每种领域对剂型、给药途径和停药期都有显着不同的考量。诊断领域包括生物感测器、病原体检测和噬菌体分型，所有这些都强调灵敏度、速度以及与检查室工作流程的整合。食品安全领域的应用主要集中在乳製品、肉类和农产品加工环节，需要在加工条件下进行严格的检验。在人类治疗领域，该领域涵盖皮肤病、胃肠道疾病、感染疾病和呼吸系统疾病，而感染疾病领域感染疾病和生物膜相关疾病带来的独特挑战而进一步细分。

噬菌体技术的区域性洞察：美洲、欧洲、中东和非洲以及亚太市场差异化驱动因素和障碍的比较

区域趋势将对噬菌体解决方案的开发、监管和市场化产生重大影响。在美洲，监管机构和采购管道强调切实可行的临床应用途径，私部门对治疗和农业应用领域的投资力度强劲。这促进了在报销和采购奖励存在的情况下快速推广应用，但也使得活体生技药品的监管变得复杂。在欧洲，监管环境各不相同。欧洲部分地区拥有完善的监管框架，有助于开展协调一致的临床试验和有条件核准，而该地区其他地区的监管成熟度则参差不齐。这些差异为区域中心的建立创造了机会，这些中心可以支持跨司法管辖区的研究和供应链。

从竞争与合作的角度出发，深入分析噬菌体产业的能力、规模、智慧财产权趋势和策略联盟，并从公司洞察的角度探讨其发展趋势。

公司层面的趋势揭示出，能力丛集、策略伙伴关係和智慧财产权组合决定着企业的竞争地位。拥有强大的研发能力、生产规模和监管经验的公司最有利于将产品推进到临床和商业管道。同时，规模小规模、专注于特定领域的生物技术公司和学术创业公司在噬菌体工程、递送技术和细分应用领域取得了重大创新，从而构建了一个从上游药物发现到下游规模化生产的充满活力的生态系统。

为行业领导者提供切实可行的建议，以加速产品开发、降低商业化风险、优化生产製造并协调监管和市场策略。

行业领导者应优先考虑将技术开发与监管策略、生产准备和终端用户参与相结合的综合方法。首先，应投资进行严格的特性分析和稳定性测试，以满足监管申报和采购竞标的预期证据要件。这将降低后期阶段的不确定性，并促进与监管机构的建设性对话。其次，生产蓝图应包含短期方案（利用契约製造组织 (CMO)）和中期计划（建立本地生产能力）。这种双轨制方法将有助于应对关税风险和供应中断。

本分析基于一套严谨的调查方法：详尽的一手和二手研究、专家检验、资料三角验证和情境分析。

本分析所依据的研究采用了混合方法，结合了与主要相关利益者的对话、全面的二手文献综述以及专家检验。主要研究包括对研究机构、契约製造、临床网路、食品加工企业和监管事务部门的领导者进行结构化访谈，以了解实际的限制因素、采购驱动因素和证据预期。这些访谈为假设的提出奠定了基础，并有助于确定最具影响力的技术趋势和市场动态的优先顺序。

简明扼要地总结了有关技术进步、监管势头、供应链韧性和相关人员策略要务的证据。

总之，噬菌体技术正处于一个转折点，科学进步、製造创新、监管合规和市场需求正在汇聚，为治疗、诊断、农业、食品安全和动物健康等领域创造实际机会。日趋成熟的工程技术，以及製剂和检测技术的进步，正催生出更精准实用的解决方案。同时，不断完善的法规结构也日益认可噬菌体产品的特殊性质。供应链设计和海关环境正在影响生产位置和采购方面的战术性决策，凸显了韧性和多元化的战略重要性。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 在医院对抗多重抗药性感染疾病的斗争中，噬菌体疗法正越来越多地被用作抗生素的替代方案。
  • 利用先进基因组学技术开发工程噬菌体，以根除畜牧业中的特定细菌病原体
  • 全球对慢性伤口管理和糖尿病溃疡治疗的个人化噬菌体混合物的投资不断增加
  • 监管协调工作旨在加速欧洲和美国市场噬菌体疗法临床试验的核准流程。
  • 噬菌体衍生的酵素已成为污染防治的新型生物防治剂。
  • 透过生技Start-Ups与学术机构的合作，加速合成噬菌体库的发现

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按应用分類的噬菌体市场

  • 农业
    • 植物保护
    • 种子处理
    • 土壤改良
  • 动物健康
    • 水产养殖
    • 伴侣动物
    • 家畜
  • 诊断
    • 生物感测器
    • 病原体检测
    • 噬菌体分型
  • 食品安全
    • 乳製品
    • 肉类
    • 农产品
  • 人类治疗
    • 皮肤科
    • 消化器官系统
    • 感染疾病
      • 细菌感染疾病
      • 生物膜相关
    • 呼吸系统

9. 依最终用户分類的噬菌体市场

  • 畜牧场
  • 食品加工公司
  • 医院
  • 研究所

第十章 依噬菌体类型分類的噬菌体市场

  • 改良噬菌体
  • 裂解噬菌体
  • 温和噬菌体

11. 依给药途径分類的噬菌体市场

  • 吸入
  • 静脉注射
  • 口服
  • 局部用药

12. 依製剂分類的噬菌体市场

  • 胶囊製剂
  • 液体配方
  • 冷冻干燥製剂

13. 依生产流程分類的噬菌体市场

  • 发酵
  • 合成製造

第十四章 各地区噬菌体市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 噬菌体市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国噬菌体市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Locus Biosciences, Inc.
    • Armata Pharmaceuticals, Inc.
    • Adaptive Phage Therapeutics, Inc.
    • Intralytix, Inc.
    • Pherecydes Pharma SA
    • BiomX, Inc.
    • PhagoMed Biopharma GmbH
    • eligo Bioscience SAS
    • enBiotix, Inc.
    • Proteon Pharmaceuticals SA
Product Code: MRR-1A1A064C03A9

The Bacteriophage Market is projected to grow by USD 76.61 million at a CAGR of 5.44% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 50.15 million
Estimated Year [2025] USD 52.83 million
Forecast Year [2032] USD 76.61 million
CAGR (%) 5.44%

Strategic introduction to bacteriophage technologies and market realities shaping research, development, regulatory dialogue, and cross-sector adoption pathways

Bacteriophage science has evolved from a niche microbiological discipline into a multidisciplinary platform that intersects therapeutics, diagnostics, agriculture, food safety, and animal health. Recent advances in genomic engineering, formulation science, and scalable production platforms have increased the technical feasibility of phage-based solutions, while parallel improvements in rapid pathogen detection and phage typing have strengthened the value proposition for targeted interventions. Consequently, stakeholders across research institutions, hospitals, food processors, and farms are reassessing where bacteriophages fit within broader antimicrobial stewardship and biosecurity strategies.

At the same time, regulatory frameworks are gradually adapting to accommodate novel biologics that do not conform to traditional small-molecule paradigms. This transition imposes new evidentiary expectations while also opening pathways for conditional and compassionate use in selected settings. In addition, the growth of contract manufacturing and modular fermentation capabilities is lowering the barrier to scale for specialized producers, even as supply chain complexity persists for critical reagents and equipment. Taken together, these structural shifts are reshaping investment priorities, partnership models, and product roadmaps for companies operating in the bacteriophage ecosystem.

This introduction sets the stage for deeper analysis of the technological enablers, market-facing requirements, and cross-sector adoption dynamics that inform strategic decisions today and in the coming planning horizons.

Identifying transformative shifts in bacteriophage science, commercialization, clinical acceptance, and manufacturing that are driving new strategic inflection points

In recent years a cluster of transformative forces has redefined how bacteriophages move from laboratory concepts to deployable solutions. Advances in precision genome editing have enabled engineered phages with tailored host ranges and payloads, increasing both efficacy and commercial attractiveness. Simultaneously, improvements in rapid diagnostics and biosensor integration have strengthened the clinical and on-farm utility of phage products by reducing time-to-target and enabling adaptive treatment strategies. These technological convergences are catalyzing a shift from one-size-fits-all approaches to more modular, targeted product architectures.

Operationally, there is an accelerating emphasis on manufacturing robustness and formulation stability, with encapsulation and lyophilization techniques extending shelf life and enabling broader routes of administration. This capacity expansion is occurring alongside new regulatory dialogues that emphasize safety, traceability, and post-market surveillance, thereby influencing trial design and go-to-market sequencing. Moreover, cross-sector collaborations-linking academic labs, contract manufacturers, and clinical networks-are creating hybrid commercialization models that spread technical risk while concentrating expertise where it matters most.

As a result, incumbents and new entrants must reassess their value propositions, invest selectively in platform capabilities, and build flexible supply chain arrangements to capture emergent opportunities across therapeutics, diagnostics, agriculture, and food safety.

Assessing the cumulative impact of United States tariffs in 2025 on bacteriophage supply chains, cost structures, international trade flows, and domestic production

Tariff policy in the United States during 2025 has the potential to materially influence the economics and logistics of bacteriophage product development and distribution. Tariff-induced cost pressures on imported laboratory reagents, specialized single-use systems, and analytical instrumentation can increase upstream expenses for both research organizations and contract manufacturers. Consequently, procurement strategies are likely to pivot toward suppliers with domestic capacity or diversified sourcing arrangements, and companies will need to incorporate tariff risk into procurement planning and price negotiations.

Beyond direct cost impacts, tariffs can alter cross-border collaboration patterns. When import duties raise the cost of key inputs or finished goods, organizations may accelerate domestic partnerships or invest in local manufacturing to preserve margins and maintain supply continuity. This trend is particularly relevant for high-value, temperature-sensitive formulations where logistics complexity already commands significant attention. Conversely, tariffs can reduce the competitiveness of exported phage-based products, prompting exporters to seek tariff mitigation through product localization, co-manufacturing agreements, or tariff classification strategies that favor lower-duty pathways.

Regulatory and procurement stakeholders should also consider the secondary effects of tariff regimes on innovation pipelines. Increased import costs may incentivize manufacturers to optimize production processes, reduce reliance on single-sourced components, and pursue synthetic or fermentation-based workflows that are less exposed to cross-border tariff volatility. In short, tariffs in 2025 are not simply a near-term cost issue; they are a catalyst for supply chain redesign, strategic localization, and operational resilience that will shape the bacteriophage landscape beyond an immediate fiscal cycle.

Key segmentation insights revealing how applications, end users, phage typologies, administration routes, formulations, and production methods influence commercialization

Segmentation analysis clarifies where technical requirements, adoption dynamics, and commercial models diverge across applications, end users, phage types, administration routes, formulation choices, and production processes. In the application domain, bacteriophage use cases span Agriculture, Animal Health, Diagnostics, Food Safety, and Human Therapeutics. Within Agriculture the emphasis is split among plant protection, seed treatment, and soil amendment, each demanding different stability, delivery, and regulatory evidence profiles. Animal Health subdivides into aquaculture, companion animals, and livestock, where dosage forms, route of administration, and withdrawal considerations vary considerably. Diagnostics includes biosensors, pathogen detection, and phage typing, all of which place a premium on sensitivity, speed, and integration with laboratory workflows. Food Safety applications concentrate on dairy, meat, and produce pathways, requiring robust validation under processing conditions. Human Therapeutics covers dermatology, gastrointestinal, infectious diseases, and respiratory indications, with infectious diseases further differentiated by the specific challenges posed by bacterial infections and biofilm-associated conditions.

Complementing application-focused segmentation, end users encompass animal farms, food processing companies, hospitals, and research institutions, each with distinct procurement cycles, risk tolerances, and operational constraints. Phage typologies-engineered phages, lytic phages, and temperate phages-carry divergent regulatory and IP considerations that affect development timelines and partner selection. Administration routes including inhalation, intravenous, oral, and topical determine formulation strategy and cold chain needs, while formulation formats such as encapsulated, liquid, and lyophilized presentations influence shelf life and logistics. Finally, production choices between fermentation and synthetic manufacturing govern scalability, cost structure, and upstream supply dependencies. Together these segmentation layers create a complex matrix of product design and go-to-market options, and they underscore the importance of aligning technical capabilities with the specific requirements of target applications and end users.

Regional insights highlighting differentiated drivers and barriers across the Americas, Europe Middle East and Africa, and Asia Pacific markets for bacteriophage technologies

Regional dynamics materially affect how bacteriophage solutions are developed, regulated, and adopted across different markets. In the Americas regulatory agencies and procurement channels emphasize pragmatic pathways for clinical access, and there is strong private-sector investment in both therapeutic and agricultural applications. This results in rapid adoption in contexts where reimbursement or procurement incentives exist, but also requires navigation of complex federal and state-level oversight for live biologics. In Europe, Middle East & Africa, the regulatory landscape is heterogeneous: parts of Europe have advanced frameworks that facilitate clinical trial harmonization and conditional approvals, while other jurisdictions within the broader region present varying levels of regulatory maturity. These differences create opportunities for regional hubs that can support multi-jurisdictional studies and supply chains.

In Asia-Pacific, the combination of large agricultural sectors, high-density aquaculture operations, and emerging biotech innovation clusters is driving a distinct set of use cases and commercialization approaches. Regulatory modernization in several Asia-Pacific markets is accelerating local clinical workstreams and domestic manufacturing capacity, which in turn supports faster on-the-ground deployment. Across all regions there is a consistent premium on building local evidence of efficacy and safety, addressing logistics and cold chain challenges, and establishing trusted distribution channels. Moreover, regional procurement policies and tariff environments influence where organizations choose to site production and how they structure cross-border partnerships.

Competitive and collaborative company insights emphasizing capabilities, scale, intellectual property trends, and strategic partnerships shaping the bacteriophage landscape

Company-level dynamics reveal a landscape where capability clusters, strategic partnerships, and IP portfolios determine competitive positioning. Firms that combine robust R&D operations with manufacturing scale and regulatory experience are best positioned to move products into clinical and commercial channels. At the same time, smaller specialized biotechs and academic spinouts contribute critical innovation around phage engineering, delivery technologies, and niche applications, creating a vibrant ecosystem of upstream discovery and downstream scale-up.

Partnership models are particularly important: contract development and manufacturing organizations, diagnostic integrators, and agriculture-focused distributors provide the operational muscle that enables innovators to reach end users. Intellectual property strategies matter not only for protecting engineered constructs but also for securing freedom to operate around manufacturing processes and formulation technologies. Additionally, companies that proactively engage with regulatory agencies and invest in transparent safety and surveillance programs tend to reduce commercialization timelines and build trust with purchasing decision-makers.

Finally, access to capital and the ability to demonstrate reproducible manufacturing and clinical evidence remain critical gating factors. Investors and partners are increasingly looking for demonstrable translational milestones, credible risk mitigation plans, and the operational readiness to scale production while maintaining stringent quality control.

Actionable recommendations for industry leaders to accelerate development, de-risk commercialization, optimize manufacturing, and align regulatory and market strategies

Industry leaders should prioritize an integrated approach that links technology development with regulatory strategy, manufacturing readiness, and end-user engagement. First, invest in rigorous characterization and stability studies that align with anticipated evidence requirements for regulatory submissions and procurement tenders. This reduces later-stage uncertainty and facilitates constructive dialogue with authorities. Second, design manufacturing roadmaps that include both short-term options through contract manufacturing organizations and medium-term plans for localized capacity; such dual-track approaches help manage tariff exposures and supply interruptions.

Third, pursue targeted partnerships that connect discovery teams with distribution channels in hospitals, food processing, and agricultural sectors. These relationships accelerate adoption by embedding phage solutions into existing operational workflows and by generating real-world performance data. Fourth, adopt a modular product architecture that accommodates different administration routes and formulation formats, thereby increasing addressable use cases while streamlining development effort. Finally, build a transparent post-market surveillance framework to monitor efficacy, resistance patterns, and safety, and use that evidence to refine indications, dosing strategies, and messaging to payers and procurement bodies.

Taken together, these recommendations support de-risked commercialization, scalable manufacturing, and credible engagement with regulators and end users, enabling organizations to convert scientific potential into sustained impact.

Robust research methodology detailing primary and secondary approaches, expert validation, data triangulation, and scenario analysis used to underpin findings

The research underpinning this analysis used a mixed-methods approach combining primary stakeholder engagement with exhaustive secondary review and expert validation. Primary research included structured interviews with leaders in research institutions, contract manufacturing, clinical networks, food processing operations, and regulatory affairs to capture real-world constraints, procurement drivers, and evidence expectations. These interviews informed hypothesis generation and helped prioritize the most consequential technology and market dynamics.

Secondary research encompassed peer-reviewed literature, regulatory guidance documents, patent filings, and publicly available technical briefs to map technological trajectories and historical precedent. Data triangulation methods were applied to reconcile differing perspectives, and scenario analysis was used to stress-test assumptions about supply chain shocks, regulatory timelines, and adoption velocity. Expert panels provided iterative validation of key findings and guided the construction of strategic recommendations, while methodological transparency was maintained through documented interview protocols, source logs, and a reproducible analytical framework.

This blended methodology ensures the conclusions are grounded in empirical observation, validated by domain experts, and robust to a range of plausible futures, thereby supporting actionable decision-making for executives and investors.

Concise conclusion synthesizing evidence on technological progress, regulatory momentum, supply chain resilience, and strategic imperatives for stakeholders

In conclusion, bacteriophage technologies are at an inflection point where scientific progress, manufacturing innovation, regulatory adaptation, and market demand converge to create tangible opportunities across therapeutics, diagnostics, agriculture, food safety, and animal health. The maturation of engineering techniques, coupled with advances in formulation and detection technologies, enables more precise and deployable solutions, while evolving regulatory frameworks are gradually accommodating the special characteristics of phage-based products. Supply chain design and tariff environments will influence tactical decisions about production siting and sourcing, underscoring the strategic importance of resilience and diversification.

Companies that succeed will be those that align rigorous technical evidence with pragmatic manufacturing plans, proactive regulatory engagement, and deep end-user partnerships. By adopting modular product architectures, investing in demonstrable safety and surveillance programs, and building flexible supply chains, organizations can move from proof-of-concept to routine deployment. Ultimately, the most consequential progress will stem from integrated approaches that convert scientific capability into operationally reliable, economically viable, and clinically or operationally effective solutions for the stakeholders who depend on them.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of phage therapy as an alternative to antibiotics in hospitals battling multidrug-resistant infections
  • 5.2. Development of engineered bacteriophages using advanced genomics for targeted bacterial pathogen eradication in livestock farming
  • 5.3. Increasing investment in personalized phage cocktails for chronic wound management and diabetic ulcer treatment globally
  • 5.4. Regulatory harmonization initiatives facilitating accelerated approval pathways for clinical phage therapy trials in Western markets
  • 5.5. Emergence of phage-derived enzymes as novel biocontrol agents to address contamination in food processing and preservation
  • 5.6. Collaborations between biotech startups and academic institutions to accelerate discovery of synthetic phage libraries

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bacteriophage Market, by Application

  • 8.1. Agriculture
    • 8.1.1. Plant Protection
    • 8.1.2. Seed Treatment
    • 8.1.3. Soil Amendment
  • 8.2. Animal Health
    • 8.2.1. Aquaculture
    • 8.2.2. Companion Animals
    • 8.2.3. Livestock
  • 8.3. Diagnostics
    • 8.3.1. Biosensors
    • 8.3.2. Pathogen Detection
    • 8.3.3. Phage Typing
  • 8.4. Food Safety
    • 8.4.1. Dairy
    • 8.4.2. Meat
    • 8.4.3. Produce
  • 8.5. Human Therapeutics
    • 8.5.1. Dermatology
    • 8.5.2. Gastrointestinal
    • 8.5.3. Infectious Diseases
      • 8.5.3.1. Bacterial Infections
      • 8.5.3.2. Biofilm Associated
    • 8.5.4. Respiratory

9. Bacteriophage Market, by End User

  • 9.1. Animal Farms
  • 9.2. Food Processing Companies
  • 9.3. Hospitals
  • 9.4. Research Institutions

10. Bacteriophage Market, by Phage Type

  • 10.1. Engineered Phages
  • 10.2. Lytic Phages
  • 10.3. Temperate Phages

11. Bacteriophage Market, by Administration Route

  • 11.1. Inhalation
  • 11.2. Intravenous
  • 11.3. Oral
  • 11.4. Topical

12. Bacteriophage Market, by Formulation

  • 12.1. Encapsulated Formulation
  • 12.2. Liquid Formulation
  • 12.3. Lyophilized Formulation

13. Bacteriophage Market, by Production Process

  • 13.1. Fermentation
  • 13.2. Synthetic Manufacturing

14. Bacteriophage Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Bacteriophage Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Bacteriophage Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Locus Biosciences, Inc.
    • 17.3.2. Armata Pharmaceuticals, Inc.
    • 17.3.3. Adaptive Phage Therapeutics, Inc.
    • 17.3.4. Intralytix, Inc.
    • 17.3.5. Pherecydes Pharma SA
    • 17.3.6. BiomX, Inc.
    • 17.3.7. PhagoMed Biopharma GmbH
    • 17.3.8. eligo Bioscience SAS
    • 17.3.9. enBiotix, Inc.
    • 17.3.10. Proteon Pharmaceuticals S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BACTERIOPHAGE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BACTERIOPHAGE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BACTERIOPHAGE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BACTERIOPHAGE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS BACTERIOPHAGE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL BACTERIOPHAGE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BACTERIOPHAGE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. BACTERIOPHAGE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BACTERIOPHAGE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BACTERIOPHAGE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BACTERIOPHAGE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PLANT PROTECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PLANT PROTECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PLANT PROTECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PLANT PROTECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PLANT PROTECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PLANT PROTECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SEED TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SEED TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SEED TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SEED TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SEED TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SEED TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SOIL AMENDMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SOIL AMENDMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SOIL AMENDMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SOIL AMENDMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SOIL AMENDMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SOIL AMENDMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AQUACULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AQUACULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BACTERIOPHAGE MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BACTERIOPHAGE MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BACTERIOPHAGE MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BACTERIOPHAGE MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BACTERIOPHAGE MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BACTERIOPHAGE MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIVESTOCK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIVESTOCK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOSENSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOSENSORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOSENSORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOSENSORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOSENSORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOSENSORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PATHOGEN DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PATHOGEN DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PATHOGEN DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PATHOGEN DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PATHOGEN DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PATHOGEN DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DAIRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DAIRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DAIRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DAIRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DAIRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DAIRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BACTERIOPHAGE MARKET SIZE, BY MEAT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BACTERIOPHAGE MARKET SIZE, BY MEAT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BACTERIOPHAGE MARKET SIZE, BY MEAT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BACTERIOPHAGE MARKET SIZE, BY MEAT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BACTERIOPHAGE MARKET SIZE, BY MEAT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BACTERIOPHAGE MARKET SIZE, BY MEAT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DERMATOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BACTERIOPHAGE MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BACTERIOPHAGE MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BACTERIOPHAGE MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BACTERIOPHAGE MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BACTERIOPHAGE MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BACTERIOPHAGE MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOFILM ASSOCIATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOFILM ASSOCIATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOFILM ASSOCIATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOFILM ASSOCIATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOFILM ASSOCIATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOFILM ASSOCIATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESPIRATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESPIRATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BACTERIOPHAGE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL FARMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL FARMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL FARMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL FARMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL FARMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL FARMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD PROCESSING COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD PROCESSING COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD PROCESSING COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD PROCESSING COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD PROCESSING COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD PROCESSING COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENGINEERED PHAGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENGINEERED PHAGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENGINEERED PHAGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENGINEERED PHAGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENGINEERED PHAGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENGINEERED PHAGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYTIC PHAGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYTIC PHAGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYTIC PHAGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYTIC PHAGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYTIC PHAGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYTIC PHAGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TEMPERATE PHAGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TEMPERATE PHAGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TEMPERATE PHAGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TEMPERATE PHAGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TEMPERATE PHAGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TEMPERATE PHAGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENCAPSULATED FORMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENCAPSULATED FORMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENCAPSULATED FORMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENCAPSULATED FORMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENCAPSULATED FORMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENCAPSULATED FORMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIQUID FORMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIQUID FORMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIQUID FORMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIQUID FORMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIQUID FORMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIQUID FORMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYOPHILIZED FORMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYOPHILIZED FORMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYOPHILIZED FORMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYOPHILIZED FORMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYOPHILIZED FORMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYOPHILIZED FORMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FERMENTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FERMENTATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FERMENTATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FERMENTATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FERMENTATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FERMENTATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SYNTHETIC MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SYNTHETIC MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SYNTHETIC MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SYNTHETIC MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SYNTHETIC MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SYNTHETIC MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL BACTERIOPHAGE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL BACTERIOPHAGE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS BACTERIOPHAGE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS BACTERIOPHAGE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS BACTERIOPHAGE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 312. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 314. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2025-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 320. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 321. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2024 (USD MILLION)
  • TABLE 322. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2025-2032 (USD MILLION)
  • TABLE 323. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2024 (USD MILLION)
  • TABLE 324. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2025-2032 (USD MILLION)
  • TABLE 325. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 326. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 327. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2024 (USD MILLION)
  • TABLE 328. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2025-2032 (USD MILLION)
  • TABLE 329. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 330. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 331. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 332. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 333. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 335. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 338. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 339. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 340. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 341. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2024 (USD MILLION)
  • TABLE 342. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2025-2032 (USD MILLION)
  • TABLE 343. EUROPE, MIDDLE EAST & A